Ileal Carcinoid – Evidence‑Based Diagnostic and Therapeutic Guidelines

Diagnostic Workup

Initial biochemical testing – For any adult with suspected ileal carcinoid, obtain plasma chromogranin A and a 24‑hour urinary 5‑HIAA as the first‑line laboratory work‑up. The recommendation is supported by the Gut series of studies. 1
Chromogranin A – Serves as the primary pan‑neuroendocrine marker and should be measured in all patients, irrespective of the presence of carcinoid syndrome. Evidence from Gut. 1
24‑hour urinary 5‑HIAA – Elevated in ≈ 70 % of mid‑gut (ileal) carcinoids and has a specificity of ~90 % for carcinoid syndrome. Data from Gut. 2
Pre‑collection dietary restrictions – Patients must avoid avocados, bananas, pineapples, plums, walnuts, tomatoes, coffee, and alcohol for 48 hours before and during urine collection to prevent false‑positive results. NCCN guideline. 4
Medication interference – Drugs such as acetaminophen, ephedrine, phenobarbital (false‑positives) and levodopa, aspirin (false‑negatives) should be discontinued or accounted for when interpreting results. NCCN guideline. 4

Baseline cross‑sectional imaging – Multi‑phase CT or MRI of the abdomen and pelvis is the recommended initial modality for detecting the primary ileal tumor and assessing metastatic spread. NCCN guideline. 4
Functional imaging – Somatostatin‑receptor scintigraphy (OctreoScan) or ⁶⁸Ga‑DOTATATE PET/CT should be performed to evaluate receptor status, guide therapy selection, and uncover occult metastases. NCCN guideline. 4

Nodal and hepatic involvement at diagnosis – Approximately 60 % of small‑bowel neuroendocrine tumors have nodal metastases, and about 30 % have liver metastases at presentation. Gut data. 1
Carcinoid syndrome prevalence and symptoms – Occurs in ~20 % of ileal carcinoids, usually indicating liver metastases; typical manifestations are dry flushing (≈ 70 %), diarrhea (≈ 50 %) and intermittent abdominal pain (≈ 40 %). Gut. 1
Pain aetiology – Abdominal pain may stem from bowel obstruction, mesenteric ischemia due to desmoplastic reaction, or direct tumor invasion. Gut. 1

Octreotide prophylaxis – Administer an IV bolus of 100–200 µg octreotide before any surgical or interventional procedure, followed by a continuous infusion of 50 µg/h intra‑operatively; continue the infusion for 24–48 h post‑operatively and taper slowly to prevent carcinoid crisis. Praxis guideline (only source available). 6
Cardiac assessment – Obtain a baseline transthoracic echocardiogram and cardiology consultation before major surgery; 59 % of patients with carcinoid syndrome have tricuspid regurgitation. NCCN guideline. 5

Somatostatin analog initiation – Start octreotide LAR 20–30 mg intramuscularly every 4 weeks (or lanreotide 120 mg SC every 4 weeks) as the primary treatment for symptom control and tumor growth inhibition. NCCN guideline. 5
Bridging with short‑acting octreotide – Add subcutaneous octreotide 150–250 µg three times daily for the first 10–14 days after initiating the long‑acting formulation to achieve therapeutic levels promptly. NCCN guideline. 4
Efficacy evidence (PROMID trial) – Octreotide LAR more than doubled time‑to‑progression (14.3 months vs 6.0 months) compared with placebo in patients with metastatic mid‑gut carcinoids (high‑level RCT evidence). NCCN guideline. 5

Octreotide LAR – Increase to 40 mg every 4 weeks or shorten the interval to every 3 weeks for breakthrough symptoms. Praxis guideline. 6
Lanreotide – Escalate to 120 mg every 3 weeks or consider 180 mg every 4 weeks. Praxis guideline. 6
Adjunct short‑acting octreotide – Use as needed for breakthrough flushing or diarrhea. NCCN guideline. 5

Resection of limited hepatic metastases – When technically feasible, complete hepatic metastasectomy yields a 10‑year overall survival of ~50.4 %. NCCN guideline. 4
Palliative primary‑tumor resection – Indicated for symptomatic patients with intermittent bowel obstruction or mesenteric ischemia, even if distant metastases are unresectable. NCCN guideline. 4
Asymptomatic primary in unresectable disease – Routine resection is generally not recommended. NCCN guideline. 4

Peptide‑receptor radionuclide therapy (PRRT) – ⁷⁷Lu‑DOTATATE should be considered for somatostatin‑receptor‑positive tumors refractory to maximal somatostatin‑analog therapy. Praxis guideline. 6
Interferon‑α – Add 3–5 million IU subcutaneously 3–5 times weekly when somatostatin analogs at maximal dose fail to control symptoms. Praxis guideline. 6
Adjuncts for refractory diarrhea – Use pancreatic enzyme supplements or cholestyramine to mitigate persistent diarrhoea despite optimal somatostatin‑analog therapy. Praxis guideline. 6

Biochemical surveillance – Measure 24‑hour urinary 5‑HIAA and plasma chromogranin A every 3–6 months to evaluate treatment response and disease progression. NCCN guideline. 4
Cardiac risk stratification – Patients with 5‑HIAA > 300 µmol/24 h and ≥ 3 flushing episodes daily have the highest risk of carcinoid‑related heart disease and require serial echocardiographic monitoring. NCCN guideline. 5
Imaging follow‑up – Repeat cross‑sectional imaging (CT or MRI) every 3–6 months for metastatic disease, or as clinically indicated for localized disease. NCCN guideline. 4

Avoid reliance on 5‑HIAA alone – Approximately 30 % of ileal carcinoids have normal 5‑HIAA despite active disease; concurrent chromogranin A measurement is mandatory. Praxis guideline (only source). 3
Mandatory peri‑operative octreotide – Do not proceed to surgery without octreotide prophylaxis in patients with known or suspected carcinoid syndrome, as carcinoid crisis carries significant mortality. Praxis guideline. 6